Navigation Links
XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors
Date:6/20/2008

MENLO PARK, Calif., June 20 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) announced today that Christopher M. Smith and Arthur T. Taylor have been appointed to the company's board of directors.

"We expect to benefit greatly from the complementary skill sets that Chris and Art will add to our board of directors," said Gregory D. Casciaro, XTENT's President and CEO. "Both are medical device industry veterans whose experience and insight will be invaluable as we move toward commercialization of the Custom NX(R) Drug Eluting Stent System."

Smith is currently president of Cochlear Americas, a developer of implantable hearing devices. From October 2003 to August 2004, he was a consultant for Warburg Pincus, a private equity firm. From 2000 to 2003, Mr. Smith served as group president for Gyrus Group Plc, (a UK listed company), and as president and CEO-Director of Gyrus Medical. Smith, who currently serves on the board of a private company, received his B.S. in Journalism and Marketing from Texas A&M University.

Taylor served as a senior executive at Kyphon Products, Spinal & Biologics Business at Medtronic Inc. from November 2007 to May 2008. Prior to that, he was chief operating officer of Kyphon, a medical device company, from 2006 until the company's acquisition by Medtronic in November 2007, having served as chief financial officer of Kyphon from 2004 to 2006. Prior to joining Kyphon, he was senior vice president and chief financial officer of Terayon Communication Systems (subsequently acquired by Motorola), a broadband access and video processing technology company. Taylor holds a B.S. in Business Administration from San Diego State University and an M.B.A. from the University of Southern California.

Robert "Robin" Bellas of Morgenthaler Ventures, a founding venture capital investor in XTENT and a board member since 2002, will leave his board position this month as the new members assume their duties. "Robin's support and service to XTENT since our first days as a company have been invaluable. We are grateful for his guidance and contributions to our growth and maturation as a company," added Casciaro.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the size of the market for its products, the timing of the commercial launch of its products and the outcomes for treated patients. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's quarterly report on Form 10-Q for the quarter ended March 31, 2008. This quarterly report was filed with the SEC on May 13, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention
2. XTENT to Present at Cowen and Companys 28th Annual Health Care Conference
3. XTENT Announces 2007 Financial Results
4. New study shows extent of harmful human influences on global ecosystems
5. XTENT Announces 2007 Financial Results Conference Call
6. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
7. XTENT Announces Third Quarter 2007 Financial Results
8. SAND Technology Appoints Zainab Ahmed Schwartz as CFO
9. eDiets.com(R) Appoints New Chief Information Officer Laura Klein
10. Healthation CEO Appoints New Senior Vice President of Business Development
11. China Yingxia International, Inc. Appoints Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: